AMGN Price Prediction Next Week
Technical Analysis
Based on the technical indicators and recent price action, AMGN shows a consolidation pattern. The stock has been receiving positive momentum from recent clinical trial results.
News Impact Recent positive developments for AMGN include:
- Strong fundamental rating of 77% from Validea's P/B Growth Investor model
- Successful Phase III WAYPOINT trial results for TEZSPIRE, showing significant reduction in nasal polyp severity and surgery needs
Price Prediction for Next Week Based on technical analysis and positive news sentiment:
- Support level: $275
- Resistance level: $290
- Target price: $285
Trading Recommendation BUY with the following parameters:
- Entry point: $278-280
- Stop loss: $274
- Take profit: $285-290
The positive clinical trial results and strong fundamental ratings provide upward momentum, while technical indicators suggest a potential breakout from current consolidation. The stock shows favorable risk-reward ratio for a long position with defined support levels.
AMGN Similar Chart Price Prediction
The price of AMGN is predicted to go up 3.85%, based on the high correlation periods with BRO. The similarity of these two price pattern on the periods is 97.03%.
AMGN
BRO
Up: 3.85%Similarity: 97.03%
AMGN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
AMGN Price Forecast($)
Potential Return(%)
2025
260.500
-0.280
2026
350.000
13.610
2027
380.000
23.350
2028
400.000
29.840
2029
400.000
29.840
2030
450.000
46.080
What is AMGN stock price prediction 2025 ?
What is AMGN stock price prediction 2026 ?
What is AMGN stock price prediction 2027 ?
What is AMGN stock price prediction 2028 ?
What is AMGN stock price prediction 2029 ?
What is AMGN stock price prediction 2030 ?
AMGN Revenue Forecast
AMGN EPS Forecast
AMGN FAQs
What is AMGN revenue forecast for next quarter？
What is AMGN eps forecast for next quarter？
AMGN VS S&P500
Amgen's pipeline had been stale since the launch of Prolia/Xgeva, but cholesterol drug Repatha and migraine drug Aimovig revived our enthusiasm for the firm's research engine, and Blincyto and Tezspire also look differentiated.
The acquisition of Decode gave Amgen the ability to identify potential new drug targets, validated by human genetics, and the firm continues to build on this database.
Amgen's improved manufacturing efficiency not only will benefit gross margins but also could give the firm a cost advantage in the biosimilar market.
AMGN Analyst's Forecast
David Amsellem
Piper Sandler
Buy
2025-02-10
Price Target
$310 → $329
Upside
+11.96%
Piper Sandler raised the firm's price target on Amgen to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the PSC Biopharma Research team recently co-hosted its Virtual TSLP Day, which featured virtual fireside chats with a number of thymic stromal lymphopoietin-focused companies, inclusive of Amgen. Piper gained additional insights into how Amgen is thinking about expansion opportunities for Tezspire beyond severe asthma, as well as how management is thinking about next-generation TSLP-directed compounds. All told, the firm continues to view Tezspire alone as a multi-billion-dollar U.S. opportunity, and one of Amgen's most consequential top-line drivers longer-term.
Robyn Karnauskas
Truist Securities
Hold
2025-01-08
Price Target
$333 → $298
Upside
+13.35%
David Amsellem
Piper Sandler
Buy
2025-01-02
Price Target
$344 → $310
Upside
+19.55%
